Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Adding a third inhaler could be the key to asthma remission. A post hoc analysis of two phase 3 trials found that triple inhaler therapy (ICS/LABA/LAMA) raised the odds of clinical remission by 44% over dual therapy in adults with moderate-to-severe uncontrolled asthma. The findings suggest optimizing inhaled treatment before escalating to biologics.
Adding a third inhaler could be the key to asthma remission. A post hoc analysis of two phase 3 randomized controlled trials — TRIMARAN and TRIGGER — found that upgrading from dual inhaler therapy (ICS/LABA) to triple therapy (ICS/LABA/LAMA) significantly improved the chances of clinical remission in adults with moderate-to-severe asthma that remained uncontrolled on the dual regimen.
The analysis pooled data from over 2,200 adults across both trials. Patients on triple therapy (beclometasone/formoterol/glycopyrronium) were compared to those continuing dual therapy (beclometasone/formoterol) over 52 weeks. Clinical remission required staying free of oral corticosteroids and severe flare-ups, achieving strong symptom control scores, and maintaining or improving lung function.
By the Numbers:
Why it matters: These findings support optimizing inhaled therapy — rather than jumping straight to costly biologic treatments — as a viable path to remission for many asthma patients. Patients with less severe baseline disease stood the best chance of achieving remission.
